^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

TRIM55 (Tripartite Motif Containing 55)

i
Other names: TRIM55, Tripartite Motif Containing 55, MURF-2, RNF29, Tripartite Motif-Containing Protein 55, Muscle-Specific RING Finger Protein 2, Ring Finger Protein 29, MuRF2, Tripartite Motif-Containing 55, Muscle Specific Ring Finger 2, RING Finger Protein 29, MuRF-2, MURF2
Associations
Trials
over1year
TRIM55 restricts the progression of hepatocellular carcinoma through ubiquitin-proteasome-mediated degradation of NF90. (PubMed, Cell Death Discov)
Furthermore, TRIM55 attenuated the association between NF90 and the mRNA of HIF1α and TGF-β2, consequently reducing their stability and inactivating the HIF1α/VEGF and TGFβ/Smad signaling pathways. In conclusion, our findings unveil the important roles of TRIM55 in suppressing the progression of HCC partly by promoting the degradation of NF90 and subsequently modulating its downstream pathways, including HIF1α/VEGF and TGFβ/Smad signaling.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • AFP (Alpha-fetoprotein) • TRIM5 (Tripartite Motif Containing 5) • TRIM55 (Tripartite Motif Containing 55)
over1year
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CRYAB (Crystallin Alpha B) • TRIM55 (Tripartite Motif Containing 55)
over2years
TRIM55 Promotes Proliferation of Hepatocellular Carcinoma Through Stabilizing TRIP6 to Activate Wnt/β-Catenin Signaling. (PubMed, J Hepatocell Carcinoma)
Our results indicate that TRIM55 promotes HCC proliferation by activating Wnt signaling pathways by stabilizing TRIP6. Therefore, targeting TRIM55 may be an effective therapeutic strategy to inhibit HCC growth.
Journal
|
TRIM5 (Tripartite Motif Containing 5) • TRIM55 (Tripartite Motif Containing 55)
over2years
TRIM55 inhibits colorectal cancer development via enhancing protein degradation of c-Myc. (PubMed, Cancer Med)
Taken together, our findings suggest that TRIM55 inhibits CRC tumor development via, at least in part, enhancing protein degradation of c-Myc. Targeting TRIM55 could provide a new therapeutic approach for CRC patients.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • TRIM5 (Tripartite Motif Containing 5) • TRIM55 (Tripartite Motif Containing 55)
|
MYC overexpression • MYC expression • CCND1 expression